Done – Medtronic-Covidien Deal

Medtronic has completed the 50 billion acquisition of Covidien, in the largest medical device merger of all time.

Medtronic-CovidienShares of the new company Medtronic Inc. will debut on Tuesday, January 27, on the New York Stock Exchange.

“The culmination of this acquisition marks a significant milestone in our industry, creating a company uniquely positioned to alleviate pain, restore health and extend life for more patients around the world. We can now bring together the extensive and innovative capabilities of both Medtronic and Covidien with an underlying objective to solve healthcare’s biggest challenge – expanding access and improving clinical outcomes, while lowering costs,” chairman & CEO Omar Ishrak said in prepared remarks.

“This is an exciting day for our employees as we officially join forces to pursue our shared commitment to addressing universal healthcare needs and accelerating Medtronic’s three fundamental strategies of therapy innovation, globalization and economic value. We know that our combined businesses can have a real and meaningful impact on people’s lives – helping to treat more people, in more ways and in more places around the world,” Ishrak said.

Medtronic-Covidien-piechartAccording to the press release, the transaction is valued at $49.9 billion, based on its closing price of $75.59 per share.

The new company would boast of some staggering numbers:

  • Total Revenue: $27.8 billion
  • Number of employees: 85,000 +
  • Number of countries operating in: 160 +
  • Number of patents: 53,000 + 
  • Research and Development spend: $2 billion
  • Charitable contributions: $80 million


Related Articles

  • Daniel Lace

    “We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”

  • Hand holding globe - diversity

    “Approaches to Increasing Diversity in Clinical Research and Addressing Health Inequities” offers key recommendations for device manufacturers and developers on steps they can take to increase diversity in clinical research and address health equity.

  • Sanobar Syed

    Market research and forecasting help ensure that you are investing in a device or drug that is needed and will be well received. In this article, Sanobar Syed, Associate Director of Forecasting, Market Insights and Strategies, BeiGene, highlights strategies to…

  • John Schwope

    AI not only improves data collection and analysis, it impacts which products are engaged in clinical trials, determines necessary medical criteria, helps design the trials and can even choose the best participating facilities. The result is, organizations that leverage AI…